BRONISLAVA SHTEYNGART, MD
Osteopathic Medicine at 82 St, Brooklyn, NY

7364888, Apr 29, 2008

Jul 7, 2005

11/175332

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

C12N 9/00

435183

The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.

2001003, Nov 1, 2001

Apr 5, 2001

09/826731

Jerome Owen Cantor - Bayside NY, US
Bronislava Shteyngart - Brooklyn NY, US

A61K038/47, A61K009/12

424/043000, 424/094610

The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme. Respiratory disorders include emphysema, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of lysozyme may be performed by aerosol, which can be generated by a nebulizer or by instillation. The lysozyme may be administered alone or with a carrier such as saline solution, DMSO, and alcohol, or water. It may also be used as a vehicle for the intratracheal administration of drugs or other agents to the lung. The lysozyme may be isolated from a natural source, such as eggs, or synthesized by a bioprocess, such as fermentation. The effective daily amount of lysozyme is from about 10 g/kg to about 1 mg/kg of body weight.

7166437, Jan 23, 2007

Sep 24, 2002

10/253756

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

G01N 33/53, G01N 33/537, G01N 30/90, G01N 24/00, G01N 33/557, G01N 33/543, C12N 9/00

435 71, 435 792, 435183, 436162, 436173, 436517, 436518

The subject invention is directed to the measurement of elastic fiber breakdown products in human sputum obtained from patients with emphysema and other lung diseases. Measurement of elastic fiber breakdown products may be used to monitor the progression of lung disease or to assess the efficacy of a treatment for lung disease. Such breakdown products are associated with lung injury resulting from degradation of lung elastic fibers. This process may occur in emphysema and other inflammatory disease of the lung where excess amounts of elastase are secreted by inflammatory cells. The methods for measuring elastin breakdown products in certain tissue fluids (i. e. blood, urine, bronchoalveolar lavage fluid) are well known to the art but have not been previously applied to sputum samples. The use of sputum has several advantages over other fluids, including greater specificity and ease of procurement.

7026287, Apr 11, 2006

May 12, 2003

10/435549

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

A61K 38/16

514 8, 514 2, 5303875, 530395, 424725

The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.